CD163在慢加急性乙型肝炎肝衰竭及原发性肝癌患者中的表达及临床意义
|
摘要
中文摘要第一部分CD163在慢加急性乙型肝炎肝衰竭患者中的表达及临床意义
乙型肝炎病毒感染是一个重要的世界卫生问题。它被认为是各种肝脏急慢性疾病的主要病因之一。由于某些病因的急剧发展,一些慢性乙型肝炎(CHB)患者有可能发展为肝衰竭。我们将这些由慢性乙型病毒性肝炎发展而来的肝衰竭称为慢加急性乙型肝炎肝衰竭(ACHBLF),其在所有肝衰竭病因中所占比例高达70%。
ACHBLF的发病机制尚不完全清楚,其死亡率高,预后差,因而降低肝衰竭患者的发病率和死亡率成为研究热点。寻找能预测肝衰竭的生物标志物能加强对患者的监测和治疗,降低ACHBLF患者的发病率和死亡率。目前大量临床研究发现,ACHBLF的发病可能与自身强烈的免疫反应有关,因此,充分理解ACHBLF发病过程的免疫应答十分重要。而CD163及sCD163是近期发现的与急性炎症反应过程密切相关的免疫因子。CD163的研究尚在起步阶段,CD163在ACHBLF患者的免疫过程中可能起到重要作用,但其在ACHBLF患者中扮演的角色尚不完全明确,对诊断及预后评估意义仍未确定,而这正是我们研究的重点及方向。
目的：
检测ACHBLF患者中外周血单个核细胞表面CD163及外周血血浆中sCD163的表达,明确其在急性炎性反应过程中扮演的角色及临床意义；为临床治疗ACHBLF患者寻找新的临床监测因子。
方法：
ELISA方法检测ACHBLF患者、CHB患者及正常对照组(HCs)血浆中sCD163的表达水平;流式细胞术检钡ACHBLF患者、CHB患者及HCs外周血单个核细胞CD163的阳性率和CD163平均荧光强度(MFI),应用逆转录聚合酶链反应(RT-PCR)测量ACHBLF患者、CHB患者及HCs外周血单个核细胞中CD163mRNA的表达。
结果：
1、外周血中CD163阳性的单个核细胞比率在ACHBLF患者中要明显高于CHB患者及HCs,具有显著性差异。外周血中CD163MFI在ACHBLF患者中较其他两组升高,但三组无显著性差异。
2、CD163mRNA在ACHBLF患者中的表达要明显高于CHB及HCs,具有显著性差异。
3、血浆中sCD163表达在ACHBLF患者中明显升高,且与患者预后有明显相关,在生存组患者中的血浆sCD163浓度要明显低于死亡组患者sCD163浓度,具有显著性差异。
4、血浆中sCD163表达在ACHBLF患者中与反映患者预后的MELD Score呈正相关,与HBV-DNA正相关,凝血酶原活动度负相关,与总胆红素水平无相关。
5、外周血中CD163阳性的单个核细胞比率在CHB患者中要明显高于HCs,具有显著性差异。
6、CD163mRNA在CHB患者中的表达要高于HCs,但并不具有显著性差异。
7、血浆sCD163表达在CHB患者中明显升高,高于HCs,但是升高幅度远远小于其在其ACHBLF患者中升高幅度,具有显著性差异。
结论：
作为在巨噬细胞表面特异表达的CD163在ACHBLF患者、CHB患者发病过程中起重要作用,本研究提示CD163与sCD163都可以作为ACHBLF患者有用的标志物,其中sCD163检测更为简单直接,组间差异更为明显,与疾病的严重程度明显相关。CD163与sCD163都可以作为肝衰竭患者预后的评价指标,与患者预后呈负相关。
中文摘要第二部分CD163在原发性肝癌患者中的表达及临床意义
感染乙型肝炎病毒的患者易罹患肝癌,有学者统计发现,慢性乙型肝炎及慢性乙肝后肝硬化患者罹患肝癌的几率是正常人的9-10倍。80%以上的原发性肝癌患者有乙型肝炎病毒感染,原发性肝癌(HCC)是肝脏的恶性肿瘤,在所有的恶性肿瘤中死亡率高达第5位,其五年生存率不足5%,这些数据表明,了解HCC的发病过程,进行早期诊断与风险评估对HCC患者非常重要,但是目前尚缺乏非常有效的早期预测手段及监测方法。
与肿瘤相关的增高的巨噬细胞被认为在肿瘤的病因及不良预后中扮演了重要角色,其中最近引起人们广泛兴趣的是,巨噬细胞的M2分型副群具有抗炎的作用,而抗炎因子CD163是M2副群的特异性标记,且为巨噬细胞活化的标记物,它的高表达可促进肿瘤的血管生成,纤维组织细胞重组,影响组织重建过程,在某些肿瘤的病理过程及在急慢性肝脏炎症疾病中起着重要作用。其在大量炎症性疾病及肿瘤性疾病中的广泛发现,使其有望成为近年来非常有效且易于监测的临床指标。
而且在前一部分试验中,通过对ACHBLF患者中外周血及血浆中CD163与sCD163表达水平的检测,我们明确了在急性炎症反应过程中CD163及sCD163的表达与临床预后的关系。在本实验中,我们选取了HCC患者作为研究对象,明确CD163及sCD163在HCC患者中的表达,明确其在HCC发病过程中的重要作用,了解其与临床指标及预后的联系,寻找新的发病机理及治疗方向。
目的：
探讨HCC患者中外周血单个核细胞CD163及血浆中sCD163的表达,可明确其在HCC疾病过程中扮演的角色及临床意义,为临床治疗HCC寻找监测因子,探寻新的发病机理及治疗方向。
方法：
ELISA方法检测HCC患者、LC患者、CHB患者及HCs血浆中sCD163的表达水平；流式细胞术检测HCC患者、LC患者、CHB患者及HCs外周血单个核细胞CD163的阳性率和CD163平均荧光强度；应用逆转录聚合酶链反应(RT-PCR)测量HCC患者、LC患者、CHB患者及HCs组外周血单个核细胞中CD163mRNA的表达。
结果：
1、外周血CD163阳性的单个核细胞比率在HCC患者中明显升高,组间有着显著性差异；CD163免疫荧光强度组间有显著性差异。
2、HCC患者中,CD163mRNA表达明显升高,组间具有显著性差异。
3、血浆中sCD163浓度在HCC患者中明显升高,组间具有显著性差异。
4、外周血中表达CD163的单个核细胞比率在LC患者中要明显高于HCs,具有显著性差异。
5、CD163mRNA在LC患者中的表达要高于HCs,组间具有显著性差异。
6、血浆sCD163表达在LC、CHB患者中明显升高,高于HCs,LC患者血浆sCD163升高幅度远远大于其在其CHB患者中升高幅度,具有显著性差异。
7、血浆sCD163表达水平与HCC患者的AFP、HBV-DNA、HBeAg无明显相关。
8、根据意大利CLIP评分分析,sCD163浓度与评分之间不存在明显相关性,TNM分期,Ⅲ期存在远处转移及Child C级的HCC患者的sCD163浓度要高于无远处转移Ⅰ、Ⅱ期患者,但是无显著性差异。结论：
作为在巨噬细胞表面特异表达的CD163在HCC、LC患者发病过程中起重要作用,本研究提示CD163与sCD163都可以作为HCC及LC患者有用的标志物,其中sCD163检测更为简单直接,组间差异更为明显,与疾病的严重程度明显相关。但是sCD163与临床指标在HCC患者中均无明确相关,与患者预后的联系仍需进一步实验证实。
中文摘要第三部分CD163综述
CD163结构及表达形式
单核细胞和巨噬细胞在人类免疫系统中发挥着重要作用。巨噬细胞可分为M1型亚群和M2型亚群,两种细胞分别有促炎和抗炎的作用。CD163是在已知的M2型巨噬细胞表面特异性表达的,属于清道夫受体半胱氨酸富集结构域家族B。它是一个有着130kD重量的Ⅰ型蛋白,共有5种同源异构体,结构中含有9个清道夫受体半胱氨酸富集结构域。CD13在体内共有两种存在形式：一种是以跨膜大分子的形式存在于单核巨噬细胞上；另一种是存在于血浆或其它组织液内,具有可溶性,即sCDl63。
CD163的作用
CD163可以特异地识别血红蛋白：结合珠蛋白复合体,是体内血红蛋白的特异性清道夫受体。通过清除游离的血红蛋白,CD163可起到调节人体免疫的作用。CD163还可识别肿瘤坏死因子样凋亡弱诱导因子(TWEAK),并与其特异性结合,发挥抗炎作用,担当着革兰氏阳性菌及革兰氏阴性菌监控器的角色；在炎症反应刺激下,CD163可以和自己的配体结合,转导信号,促进单核细胞与上皮细胞的黏附,诱导炎性介质IL-10等炎症因子的释放。
CD163与各种疾病的关系
CD163及sCD163与免疫系统关系密切。大量的临床及实验室研究证实,CD163及sCD163与各种炎症性、肿瘤性、心脑血管疾病密切相关。在严重烧伤、急性肝衰竭等严重炎性疾病时,CD163明显升高,与预后有明显相关;在肝癌、淋巴瘤等恶性肿瘤中,亦可见CD163的明显升高,在淋巴结转移及治疗反应不佳的病人中尤为明显,提示CD163在肿瘤患者预后监测中的重要作用。糖尿病、高血脂、冠状动脉粥样硬化性心脏病等疾病中,CD163及sCD163均已被明确证实与疾病预后明显相关。
CD163及sCD163在抗炎、促肿瘤方面的广阔前景,使其成为人们在未来研究的热门生物靶点,并已取得了初步成效。
INCREASED CD163AND SCD163IS ASSOCIATED' ACUTE-ON-CHRONIC HEPATITIS B LIVER FAIL ABSTRACT
Hepatitis B virus (HBV) infection is an important health problem worldwide. It is thought to be one of the main causes of liver related chronic and acute diseases. With severe acute exacerbation of the disease, some chronic hepatitis B (CHB) patients may progress to liver failure. We define this progression as acute-on-chronic hepatitis B liver failure (ACHBLF). It constitutes about70%of all ACLF in areas with a high incidence of hepatitis B.
ACHBLF has an extremely poor prognosis due to a lack of understanding of its pathogenesis. Thus reducing the morbidity and mortality of hepatic failure patients has become a research hotspot. The search for biomarkers which can predict hepatic failure can strengthen the monitoring and treatment of patients with liver failure and reduce the incidence and mortality of ACHBLF. Current clinical research found that there was very close relationship between the pathogenesis of ACHBLF and strong immune response. Therefore, it is very important to fully understand the immune response of ACHBLF.
In recent years, the extensive research in CD163make it possible to be an effective indicator and therapeutic target, which can be detected easily. The research of CD163is still in its infancy. However, their diagnostic and prognostic potential in patients with ACHBLF patients has not been investigated yet. That is the focus and direction of our research.
Objective:
To study the expression and significance of CD163in ACHBLF patients. We detected the surface CD163in peripheral blood mononuclear cells (PBMCs) and sCD163in peripheral blood in ACHBLF patients. We want to know the relationship between the expression of CD163, sCD163and the prognosis of patients with ACHBLF patients, and their relationship with clinical indexes and clinical significance.
Methods:
We detected the frequency of CD163+PBMCs using flow cytometry(FCM). We also evaluated the average mean fluorescence intensity (MFI) of CD163+PBMCs using FCM. Real-time transcription-polymerase chain reaction (RT-PCR) was performed to assess relative CD163mRNA levels in PBMCs. We evaluated the plasma levels of sCD163by enzyme linked immunosorbent assay (ELISA).
Results:
1. CD163positive in PBMCs in patients with ACHBLF is significantly higher than CHB patients and healthy controls(HCs), there were significant differences within three groups. However, there were no significant differences in MFI in CD163+PBMCs within three groups.
2. CD163mRNA expression in ACHBLF patients was significantly higher than CHB patients and HCs, there were significant differences within three groups.
3. Plasma sCD163expression was significantly elevated in patients with ACHBLF, and was significantly correlated with the prognosis of patients. There were significant differences within three groups.
4. Plasma levels of sCD163were positively correlated with MELD score, plasma HBV-DNA levels and negatively correlated with PTA, but had no correlation with TBIL.
5. CD163positive in PBMCs in CHB patients was significantly higher than that in HCs.
6. CD163mRNA expression in CHB patients was higher than that of HCs, there was no significant difference between two groups.
7. Plasma sCD163expression was significantly elevated in patients with CHB, there was significant difference between two groups.
Conclusion:
As expressed in the macrophage surface specific, CD163plays an important role in patients with ACHBLF and CHB in the pathogenesis.The research suggested that CD163and sCD163can be used as useful biomarkers for ACHBLF. SCD163detection is more simple and direct, with more significant group differences. It is significantly correlated with the severity of the disease. CD163and sCD163can be used as index of prognosis in patients with liver failure, and negatively correlated with the prognosis of the patients.
英文摘要第二部分
INCREASED CD163AND SCD163IS ASSOCIATED HEPATOCELLULAR CARCINOMA ABSTRACT
People who have hepatitis B are prone to have a much higher risk of suffering from hepatocellular caicinoma(HCC). Some scholars think that people who have chronic hepatitis B and liver cirrhosis with hepatitis B may have the probability of suffering from HCC9to10times higher than that of normal people. More than80%of HCC patients have hepatitis B virus infection. In all of the malignant tumors, HCC have mortality rates as high as the fifth. Its five-year survival rate is less than5%. These data show that understanding of the pathogenesis, early diagnosis and risk assessment in patients with HCC are very important. However, we lack of effective early prediction and monitoring method of HCC.
It is widely interested that TAMs have an anti-inflammatory function resembling M2macrophages. CD163is a M2macrophages specific marker and macrophage activation marker. Its high expression can promote tumor angiogenesis, restructuring, affecting fibrosis tissue cells, organizing reconstruction process. It plays an important role in the pathological process of tumors and acute or chronic inflammation of the liver diseases.
Nevertheless in the former part of experiment, we have found the high levels of CD163expression in patients with ACHBLF. We also found the relationship between the expression of CD163and sCD163and clinical prognosis in acute inflammation process. In this experiment, we selected the patients with HCC as the research object. CD163and sCD163may play an important role in patients with HCC. We are eager to know its relationship between the prognosis and clinical indexes, and look for the new direction of treatment.
Objective:
To study the expression and significance of CD163in HCC. We evalues the surface CD163on peripheral blood mononuclear cells (PBMCs) and the expression of sCD163in peripheral blood. We would like to understand the relationship between the expression of CD163and sCD163and the prognosis of patients with HCC and their relationship with clinical indexes and clinical significance.
Methods:
We determined the frequency of CD163+PBMCs using flow cytometry (FCM). We also evaluated the average mean fluorescence intensity (MFI) of CD163+PBMCs using FCM. Real-time transcription-polymerase chain reaction (RT-PCR) was performed to assess relative CD163mRNA levels in PBMCs. We evaluated the plasma levels of sCD163by enzyme linked immunosorbent assay(ELISA).
Results:
1. CD163+mononuclear cells increased significantly in patients with hepatocellular carcinoma (HCC), compared with liver cirrhosis (LC), chronic hepatitis B (CHB) and healthy controls (HCs) with significant difference. There was significant difference in mean fluorescence intensity(MFI) of CD163+PBMCS within groups.
2. In patients with HCC, CD163mRNA expression is much higher than the patients of CHB and HCs.There was significant difference within groups.
3. sCD163in plasma increased significantly in patients with HCC, and has close relationship with the prognosis of patients with HCC. There were significant differences within groups.
4. CD163+mononuclear cells increased significantly in patients with LC, compared with CHB and HCs with significant difference.
5. In patients with LC, CD163mRNA expression is higher than the patients of CHB and HCs. There was significant difference within groups.
6. sCD163in plasma increased higher in patients with LC, compared with the patients of CHB and HCs with significant differences.
7. sCD163in plasma increased significantly in patients with HCC had no associations with AFP、HBV-DNA and HBeAg.
8. There is no correlation between sCD163concentration and Italian CLIP scores. According to a2002AJCC international staging, namely the TNM staging, sCD163concentration in patients with HCC in phase Ⅲ of distant metastasis and Child C level was higher than patients in the stage Ⅰ, stage Ⅱ, but with no significance.
Conclusion:
CD163plays an important role in patients with HCC、LC in the pathogenesis. The research suggested that CD163and sCD163can be used as useful biomarkers in the treatment of patients with HCC. SCD163detection is much simpler and direct. It is significantly correlated with the severity of the disease.
英文摘要第三部分
CD163REVIEW ABSTRACT
Form and structure of CD163
Monocytes and macrophages play an important role in the human immune system. Macrophages can be divided into M1subsets and M2subsets, which have proinflammatory and anti-inflammatory effects respectively. CD163only express on the macrophage surface of M2type. It belongs to the scavenger receptor cysteine rich domain family B and is a I type protein with130kD weight. It has5homologous isoforms, with structure containing9scavenger receptor cysteine rich domains. CD163has two forms in vivo:one is a transmembrane molecule existing in the form of mononuclear macrophages; the other one present in the blood or other tissue fluid, soluble, namely sCD163.
Role of CD163
CD163can specifically recognize haptoglobin hemoglobin complex and is a hemoglobin specific scavenger receptor. Through the clearance of free hemoglobin, it can adjust the body's immune function. CD163can also identify factor of apoptosis (TWEAK). With its specific binding, it plays an important role in monitoring gram positive bacteria and gram negative bacteria. With inflammation stimulation, it can also promote monocyte adhesion to epithelial cells and induction of inflammatory mediators, such as inflammatory factors IL-10.
Relationship between CD163and various diseases
CD163and sCD163have a close relationship with the immune system. Several clinical and laboratory studies found that CD163and sCD163are very closely related with various diseases, such as inflammation, tumor, cardiovascular or cerebrovascular diseases. In severe burns, acute liver failure and other serious inflammatory diseases, CD163increased significantly and related with prognosis. CD163increased significantly in HCC and malignant lymphoma, especially in patients with lymph node metastasis and poor response to therapy. It suggests an important role of CD163in prognosis of tumor patients. CD163and sCD163have been clearly proved to be significantly associated with the prognosis of the diabetes、hyperlipidemia and coronary heart disease.
CD163and sCD163play important roles in anti-inflammation and promoting cancers, which make them popular in biological targets for future research and have already achieved initial success.
乙型肝炎病毒感染是一个重要的世界卫生问题。它被认为是各种肝脏急慢性疾病的主要病因之一。由于某些病因的急剧发展,一些慢性乙型肝炎(CHB)患者有可能发展为肝衰竭。我们将这些由慢性乙型病毒性肝炎发展而来的肝衰竭称为慢加急性乙型肝炎肝衰竭(ACHBLF),其在所有肝衰竭病因中所占比例高达70%。
ACHBLF的发病机制尚不完全清楚,其死亡率高,预后差,因而降低肝衰竭患者的发病率和死亡率成为研究热点。寻找能预测肝衰竭的生物标志物能加强对患者的监测和治疗,降低ACHBLF患者的发病率和死亡率。目前大量临床研究发现,ACHBLF的发病可能与自身强烈的免疫反应有关,因此,充分理解ACHBLF发病过程的免疫应答十分重要。而CD163及sCD163是近期发现的与急性炎症反应过程密切相关的免疫因子。CD163的研究尚在起步阶段,CD163在ACHBLF患者的免疫过程中可能起到重要作用,但其在ACHBLF患者中扮演的角色尚不完全明确,对诊断及预后评估意义仍未确定,而这正是我们研究的重点及方向。
目的：
检测ACHBLF患者中外周血单个核细胞表面CD163及外周血血浆中sCD163的表达,明确其在急性炎性反应过程中扮演的角色及临床意义；为临床治疗ACHBLF患者寻找新的临床监测因子。
方法：
ELISA方法检测ACHBLF患者、CHB患者及正常对照组(HCs)血浆中sCD163的表达水平;流式细胞术检钡ACHBLF患者、CHB患者及HCs外周血单个核细胞CD163的阳性率和CD163平均荧光强度(MFI),应用逆转录聚合酶链反应(RT-PCR)测量ACHBLF患者、CHB患者及HCs外周血单个核细胞中CD163mRNA的表达。
结果：
1、外周血中CD163阳性的单个核细胞比率在ACHBLF患者中要明显高于CHB患者及HCs,具有显著性差异。外周血中CD163MFI在ACHBLF患者中较其他两组升高,但三组无显著性差异。
2、CD163mRNA在ACHBLF患者中的表达要明显高于CHB及HCs,具有显著性差异。
3、血浆中sCD163表达在ACHBLF患者中明显升高,且与患者预后有明显相关,在生存组患者中的血浆sCD163浓度要明显低于死亡组患者sCD163浓度,具有显著性差异。
4、血浆中sCD163表达在ACHBLF患者中与反映患者预后的MELD Score呈正相关,与HBV-DNA正相关,凝血酶原活动度负相关,与总胆红素水平无相关。
5、外周血中CD163阳性的单个核细胞比率在CHB患者中要明显高于HCs,具有显著性差异。
6、CD163mRNA在CHB患者中的表达要高于HCs,但并不具有显著性差异。
7、血浆sCD163表达在CHB患者中明显升高,高于HCs,但是升高幅度远远小于其在其ACHBLF患者中升高幅度,具有显著性差异。
结论：
作为在巨噬细胞表面特异表达的CD163在ACHBLF患者、CHB患者发病过程中起重要作用,本研究提示CD163与sCD163都可以作为ACHBLF患者有用的标志物,其中sCD163检测更为简单直接,组间差异更为明显,与疾病的严重程度明显相关。CD163与sCD163都可以作为肝衰竭患者预后的评价指标,与患者预后呈负相关。
中文摘要第二部分CD163在原发性肝癌患者中的表达及临床意义
感染乙型肝炎病毒的患者易罹患肝癌,有学者统计发现,慢性乙型肝炎及慢性乙肝后肝硬化患者罹患肝癌的几率是正常人的9-10倍。80%以上的原发性肝癌患者有乙型肝炎病毒感染,原发性肝癌(HCC)是肝脏的恶性肿瘤,在所有的恶性肿瘤中死亡率高达第5位,其五年生存率不足5%,这些数据表明,了解HCC的发病过程,进行早期诊断与风险评估对HCC患者非常重要,但是目前尚缺乏非常有效的早期预测手段及监测方法。
与肿瘤相关的增高的巨噬细胞被认为在肿瘤的病因及不良预后中扮演了重要角色,其中最近引起人们广泛兴趣的是,巨噬细胞的M2分型副群具有抗炎的作用,而抗炎因子CD163是M2副群的特异性标记,且为巨噬细胞活化的标记物,它的高表达可促进肿瘤的血管生成,纤维组织细胞重组,影响组织重建过程,在某些肿瘤的病理过程及在急慢性肝脏炎症疾病中起着重要作用。其在大量炎症性疾病及肿瘤性疾病中的广泛发现,使其有望成为近年来非常有效且易于监测的临床指标。
而且在前一部分试验中,通过对ACHBLF患者中外周血及血浆中CD163与sCD163表达水平的检测,我们明确了在急性炎症反应过程中CD163及sCD163的表达与临床预后的关系。在本实验中,我们选取了HCC患者作为研究对象,明确CD163及sCD163在HCC患者中的表达,明确其在HCC发病过程中的重要作用,了解其与临床指标及预后的联系,寻找新的发病机理及治疗方向。
目的：
探讨HCC患者中外周血单个核细胞CD163及血浆中sCD163的表达,可明确其在HCC疾病过程中扮演的角色及临床意义,为临床治疗HCC寻找监测因子,探寻新的发病机理及治疗方向。
方法：
ELISA方法检测HCC患者、LC患者、CHB患者及HCs血浆中sCD163的表达水平；流式细胞术检测HCC患者、LC患者、CHB患者及HCs外周血单个核细胞CD163的阳性率和CD163平均荧光强度；应用逆转录聚合酶链反应(RT-PCR)测量HCC患者、LC患者、CHB患者及HCs组外周血单个核细胞中CD163mRNA的表达。
结果：
1、外周血CD163阳性的单个核细胞比率在HCC患者中明显升高,组间有着显著性差异；CD163免疫荧光强度组间有显著性差异。
2、HCC患者中,CD163mRNA表达明显升高,组间具有显著性差异。
3、血浆中sCD163浓度在HCC患者中明显升高,组间具有显著性差异。
4、外周血中表达CD163的单个核细胞比率在LC患者中要明显高于HCs,具有显著性差异。
5、CD163mRNA在LC患者中的表达要高于HCs,组间具有显著性差异。
6、血浆sCD163表达在LC、CHB患者中明显升高,高于HCs,LC患者血浆sCD163升高幅度远远大于其在其CHB患者中升高幅度,具有显著性差异。
7、血浆sCD163表达水平与HCC患者的AFP、HBV-DNA、HBeAg无明显相关。
8、根据意大利CLIP评分分析,sCD163浓度与评分之间不存在明显相关性,TNM分期,Ⅲ期存在远处转移及Child C级的HCC患者的sCD163浓度要高于无远处转移Ⅰ、Ⅱ期患者,但是无显著性差异。结论：
作为在巨噬细胞表面特异表达的CD163在HCC、LC患者发病过程中起重要作用,本研究提示CD163与sCD163都可以作为HCC及LC患者有用的标志物,其中sCD163检测更为简单直接,组间差异更为明显,与疾病的严重程度明显相关。但是sCD163与临床指标在HCC患者中均无明确相关,与患者预后的联系仍需进一步实验证实。
中文摘要第三部分CD163综述
CD163结构及表达形式
单核细胞和巨噬细胞在人类免疫系统中发挥着重要作用。巨噬细胞可分为M1型亚群和M2型亚群,两种细胞分别有促炎和抗炎的作用。CD163是在已知的M2型巨噬细胞表面特异性表达的,属于清道夫受体半胱氨酸富集结构域家族B。它是一个有着130kD重量的Ⅰ型蛋白,共有5种同源异构体,结构中含有9个清道夫受体半胱氨酸富集结构域。CD13在体内共有两种存在形式：一种是以跨膜大分子的形式存在于单核巨噬细胞上；另一种是存在于血浆或其它组织液内,具有可溶性,即sCDl63。
CD163的作用
CD163可以特异地识别血红蛋白：结合珠蛋白复合体,是体内血红蛋白的特异性清道夫受体。通过清除游离的血红蛋白,CD163可起到调节人体免疫的作用。CD163还可识别肿瘤坏死因子样凋亡弱诱导因子(TWEAK),并与其特异性结合,发挥抗炎作用,担当着革兰氏阳性菌及革兰氏阴性菌监控器的角色；在炎症反应刺激下,CD163可以和自己的配体结合,转导信号,促进单核细胞与上皮细胞的黏附,诱导炎性介质IL-10等炎症因子的释放。
CD163与各种疾病的关系
CD163及sCD163与免疫系统关系密切。大量的临床及实验室研究证实,CD163及sCD163与各种炎症性、肿瘤性、心脑血管疾病密切相关。在严重烧伤、急性肝衰竭等严重炎性疾病时,CD163明显升高,与预后有明显相关;在肝癌、淋巴瘤等恶性肿瘤中,亦可见CD163的明显升高,在淋巴结转移及治疗反应不佳的病人中尤为明显,提示CD163在肿瘤患者预后监测中的重要作用。糖尿病、高血脂、冠状动脉粥样硬化性心脏病等疾病中,CD163及sCD163均已被明确证实与疾病预后明显相关。
CD163及sCD163在抗炎、促肿瘤方面的广阔前景,使其成为人们在未来研究的热门生物靶点,并已取得了初步成效。
INCREASED CD163AND SCD163IS ASSOCIATED' ACUTE-ON-CHRONIC HEPATITIS B LIVER FAIL ABSTRACT
Hepatitis B virus (HBV) infection is an important health problem worldwide. It is thought to be one of the main causes of liver related chronic and acute diseases. With severe acute exacerbation of the disease, some chronic hepatitis B (CHB) patients may progress to liver failure. We define this progression as acute-on-chronic hepatitis B liver failure (ACHBLF). It constitutes about70%of all ACLF in areas with a high incidence of hepatitis B.
ACHBLF has an extremely poor prognosis due to a lack of understanding of its pathogenesis. Thus reducing the morbidity and mortality of hepatic failure patients has become a research hotspot. The search for biomarkers which can predict hepatic failure can strengthen the monitoring and treatment of patients with liver failure and reduce the incidence and mortality of ACHBLF. Current clinical research found that there was very close relationship between the pathogenesis of ACHBLF and strong immune response. Therefore, it is very important to fully understand the immune response of ACHBLF.
In recent years, the extensive research in CD163make it possible to be an effective indicator and therapeutic target, which can be detected easily. The research of CD163is still in its infancy. However, their diagnostic and prognostic potential in patients with ACHBLF patients has not been investigated yet. That is the focus and direction of our research.
Objective:
To study the expression and significance of CD163in ACHBLF patients. We detected the surface CD163in peripheral blood mononuclear cells (PBMCs) and sCD163in peripheral blood in ACHBLF patients. We want to know the relationship between the expression of CD163, sCD163and the prognosis of patients with ACHBLF patients, and their relationship with clinical indexes and clinical significance.
Methods:
We detected the frequency of CD163+PBMCs using flow cytometry(FCM). We also evaluated the average mean fluorescence intensity (MFI) of CD163+PBMCs using FCM. Real-time transcription-polymerase chain reaction (RT-PCR) was performed to assess relative CD163mRNA levels in PBMCs. We evaluated the plasma levels of sCD163by enzyme linked immunosorbent assay (ELISA).
Results:
1. CD163positive in PBMCs in patients with ACHBLF is significantly higher than CHB patients and healthy controls(HCs), there were significant differences within three groups. However, there were no significant differences in MFI in CD163+PBMCs within three groups.
2. CD163mRNA expression in ACHBLF patients was significantly higher than CHB patients and HCs, there were significant differences within three groups.
3. Plasma sCD163expression was significantly elevated in patients with ACHBLF, and was significantly correlated with the prognosis of patients. There were significant differences within three groups.
4. Plasma levels of sCD163were positively correlated with MELD score, plasma HBV-DNA levels and negatively correlated with PTA, but had no correlation with TBIL.
5. CD163positive in PBMCs in CHB patients was significantly higher than that in HCs.
6. CD163mRNA expression in CHB patients was higher than that of HCs, there was no significant difference between two groups.
7. Plasma sCD163expression was significantly elevated in patients with CHB, there was significant difference between two groups.
Conclusion:
As expressed in the macrophage surface specific, CD163plays an important role in patients with ACHBLF and CHB in the pathogenesis.The research suggested that CD163and sCD163can be used as useful biomarkers for ACHBLF. SCD163detection is more simple and direct, with more significant group differences. It is significantly correlated with the severity of the disease. CD163and sCD163can be used as index of prognosis in patients with liver failure, and negatively correlated with the prognosis of the patients.
英文摘要第二部分
INCREASED CD163AND SCD163IS ASSOCIATED HEPATOCELLULAR CARCINOMA ABSTRACT
People who have hepatitis B are prone to have a much higher risk of suffering from hepatocellular caicinoma(HCC). Some scholars think that people who have chronic hepatitis B and liver cirrhosis with hepatitis B may have the probability of suffering from HCC9to10times higher than that of normal people. More than80%of HCC patients have hepatitis B virus infection. In all of the malignant tumors, HCC have mortality rates as high as the fifth. Its five-year survival rate is less than5%. These data show that understanding of the pathogenesis, early diagnosis and risk assessment in patients with HCC are very important. However, we lack of effective early prediction and monitoring method of HCC.
It is widely interested that TAMs have an anti-inflammatory function resembling M2macrophages. CD163is a M2macrophages specific marker and macrophage activation marker. Its high expression can promote tumor angiogenesis, restructuring, affecting fibrosis tissue cells, organizing reconstruction process. It plays an important role in the pathological process of tumors and acute or chronic inflammation of the liver diseases.
Nevertheless in the former part of experiment, we have found the high levels of CD163expression in patients with ACHBLF. We also found the relationship between the expression of CD163and sCD163and clinical prognosis in acute inflammation process. In this experiment, we selected the patients with HCC as the research object. CD163and sCD163may play an important role in patients with HCC. We are eager to know its relationship between the prognosis and clinical indexes, and look for the new direction of treatment.
Objective:
To study the expression and significance of CD163in HCC. We evalues the surface CD163on peripheral blood mononuclear cells (PBMCs) and the expression of sCD163in peripheral blood. We would like to understand the relationship between the expression of CD163and sCD163and the prognosis of patients with HCC and their relationship with clinical indexes and clinical significance.
Methods:
We determined the frequency of CD163+PBMCs using flow cytometry (FCM). We also evaluated the average mean fluorescence intensity (MFI) of CD163+PBMCs using FCM. Real-time transcription-polymerase chain reaction (RT-PCR) was performed to assess relative CD163mRNA levels in PBMCs. We evaluated the plasma levels of sCD163by enzyme linked immunosorbent assay(ELISA).
Results:
1. CD163+mononuclear cells increased significantly in patients with hepatocellular carcinoma (HCC), compared with liver cirrhosis (LC), chronic hepatitis B (CHB) and healthy controls (HCs) with significant difference. There was significant difference in mean fluorescence intensity(MFI) of CD163+PBMCS within groups.
2. In patients with HCC, CD163mRNA expression is much higher than the patients of CHB and HCs.There was significant difference within groups.
3. sCD163in plasma increased significantly in patients with HCC, and has close relationship with the prognosis of patients with HCC. There were significant differences within groups.
4. CD163+mononuclear cells increased significantly in patients with LC, compared with CHB and HCs with significant difference.
5. In patients with LC, CD163mRNA expression is higher than the patients of CHB and HCs. There was significant difference within groups.
6. sCD163in plasma increased higher in patients with LC, compared with the patients of CHB and HCs with significant differences.
7. sCD163in plasma increased significantly in patients with HCC had no associations with AFP、HBV-DNA and HBeAg.
8. There is no correlation between sCD163concentration and Italian CLIP scores. According to a2002AJCC international staging, namely the TNM staging, sCD163concentration in patients with HCC in phase Ⅲ of distant metastasis and Child C level was higher than patients in the stage Ⅰ, stage Ⅱ, but with no significance.
Conclusion:
CD163plays an important role in patients with HCC、LC in the pathogenesis. The research suggested that CD163and sCD163can be used as useful biomarkers in the treatment of patients with HCC. SCD163detection is much simpler and direct. It is significantly correlated with the severity of the disease.
英文摘要第三部分
CD163REVIEW ABSTRACT
Form and structure of CD163
Monocytes and macrophages play an important role in the human immune system. Macrophages can be divided into M1subsets and M2subsets, which have proinflammatory and anti-inflammatory effects respectively. CD163only express on the macrophage surface of M2type. It belongs to the scavenger receptor cysteine rich domain family B and is a I type protein with130kD weight. It has5homologous isoforms, with structure containing9scavenger receptor cysteine rich domains. CD163has two forms in vivo:one is a transmembrane molecule existing in the form of mononuclear macrophages; the other one present in the blood or other tissue fluid, soluble, namely sCD163.
Role of CD163
CD163can specifically recognize haptoglobin hemoglobin complex and is a hemoglobin specific scavenger receptor. Through the clearance of free hemoglobin, it can adjust the body's immune function. CD163can also identify factor of apoptosis (TWEAK). With its specific binding, it plays an important role in monitoring gram positive bacteria and gram negative bacteria. With inflammation stimulation, it can also promote monocyte adhesion to epithelial cells and induction of inflammatory mediators, such as inflammatory factors IL-10.
Relationship between CD163and various diseases
CD163and sCD163have a close relationship with the immune system. Several clinical and laboratory studies found that CD163and sCD163are very closely related with various diseases, such as inflammation, tumor, cardiovascular or cerebrovascular diseases. In severe burns, acute liver failure and other serious inflammatory diseases, CD163increased significantly and related with prognosis. CD163increased significantly in HCC and malignant lymphoma, especially in patients with lymph node metastasis and poor response to therapy. It suggests an important role of CD163in prognosis of tumor patients. CD163and sCD163have been clearly proved to be significantly associated with the prognosis of the diabetes、hyperlipidemia and coronary heart disease.
CD163and sCD163play important roles in anti-inflammation and promoting cancers, which make them popular in biological targets for future research and have already achieved initial success.
引文
1 Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S. Variability in the precore and core promoter regions of HBV strains in moroccoxharacterization and impact on liver disease progression. PLoS One.2012; 7:e42891.
2 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liverfailure:Consensus recommendations of the Asian Pacific Associationfor the study of the liver (APASL). Hepatol Int.2009; 3:269-282.
3 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure:a prospective cohort study. Crit Care.2012 Nov 27;16(6):R227.
4 Wang LY, Meng QH, Zou ZQ, Fan YC, Han J, Qi ZX, Ge J, Xu AL, Wang SK, Wang K. Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure. Dig Dis Sci.2011; 57:667-674.
5 Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. Scientific World Journal.2011; 11:2391-2402.
6 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol.2011; 49:365-374.
7 Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure:a retrospective study. Mycoses.2013.
8 Zhao J, Zhang JY, Yu HW, He YL, Zhao JJ, Li J, Zhu YK, Yao QW, Wang JH, Liu HX, Shi SY, Zou ZS, Xu XS, Zhou CB, Wang FS, Meng QH. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol.2012 Sep;9(5):417-422.
9 Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, Zhao M. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett.2013; 149:41-49.
10 Li shanshan, Chen yu, DuanZhongping. CD 163 and SCD163:the newmarker of the evaluation of liver failure. J Clin Hepatol.2011; 27(10):1112-1115.
11 Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer, Williams KC, Grinspoon S.F, Rosenberg ES. Soluble CD 163, a novel marker of activated macrophages, is elevatedand associated with noncaLCified coronary plaque in HIV 20-infected patients. J Infect Dis. 2011; 204:1227-1236.
12 Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD,van den Berg TK. The macrophage scavenger receptor CD 163 functions as an innate immune sensor for bacteria. Blood.2009; 113:887-892.
13 Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J.1976; 115:1191-1192.
14 Etzerodt A, Maniecki MB, Graversen JH, M(?)ller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD 163. J Control Release.2012; 160:72-80.
15 Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD 163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One.2011; 6:e19968.
16 Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther.2010; 12:R128.
17 He WP, Hu JH, Zhao J, Tong JJ, Ding JB, Lin F, Wang HF. Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure. Chin Med J (Engl).2012; 125:2272-2278.
18 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol.2011; 9:351-356.
19 M(?)ller HJ. Soluble CD163. Scand J Clin Lab Invest.2012; 72:1-13.
20 M(?)ller HJ, Gr(?)nbaek H, Schi(?)dt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007; 47:671-676.
21 Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol.2011; 714:141.
22 Onofre G, Kolackova M, Jankovicova K, Krejsekb J. Scavenger receptor CD163 and its biological functions. ActaMedica (Hradec Kralove).2009; 52:57-61.
23 Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-Mac3:a new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936-945.
24 Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteines-rich family (CD163). J Immunol.1998; 161:1883-1890.
25 Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine.2000;12:1312-1321.
26 Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples:influence of different anticoagulants. Clin Vaccin Immunol. 2006;13:704-707.
27 Davis BH, Zarev PV. Human monocyte CD 163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom.2005; 63:16-22.
28 Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocye hemoglobin scavenger receptor CD163. J Leukoc Biol.2002; 72:711-717.
29 Weaver LK, Pioli PA, Wardwell K, Vogel SN,Guyre PM. Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol.2007; 81:663-671.
30 Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Sakai K, Inoue Y, Ihn H.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol.2012 Jul-Aug; 22(4):512-517.
31 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012; 14:914-936.
32 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries. Indian J Plast Surg. 2011; 44:118-124.
33 Holger Jon M(?)ller, MD PhD, Henning Gr(?)naek, MD PhD, Frank V. Schi(?)dt, MD PhD, PeterHol land-Fischer, MD, Michael Schilsky, MD, Santiago Munoz, MD, Tarek Hassanein, MD, and William M. Lee, MD, the US Acute Liver Failure Study Group. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007 November; 47(5):671-676.
34 Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. InfectDis.2011; 204:154-163.
35 Jude C, Samasca G, Balacescu L, Balacescu L, Blacescu O. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int.2012.
36 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and Fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
37 Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study. PLoS One.2012; 7:e38400.
38 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. & Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012;18:1732-1744.
39 Kazankov K,Barrera F,Moller HJ. Soluble CD163,a macrophage activation marker,is independently associated with fibrosis in patients with chronic hepatitis C and B. Hepatology.2014; March 13.
40 Wu hui-ling. The effect of endotoxemia on scavenger receptor CD163 in chronic on acute liver failure. [D]. Wuhan, HuaZhong TechnologyMedical school.2010.
41 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol.2012; 18:4604-4609.
42 Lai J, Li XJ, Zhang SQ, Xu QH, Zhu JY, Ke WM. The relationship of HBeAg status with HBV DNA loads, MELD scores in patients with acute-on-chronic hepatitis B liver failure during terminal phases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26:51-53.
43 Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol.2012; 27: 223-230.
44 Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F, Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. Viral Hepat.2010 Dec;17(12):887-895.
45 Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD 163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005;201(5):379-384.
1 Su L, Feng L, Liu C, Jiang Z, Li M, Xiao K, Yan P, Jia Y, Feng D, Xie L. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. Rheumatol Int.2012; 13:123.
2 Ingels C, M(?)ller HJ, Hansen TK, Wouters PJ, Vanhorebeek I, Van den Berghe G. Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients. J Clin Immunol.2013; 33:619-629.
3 Qu, J.H., Chang, X.J., Lu,Y.Y., Bai, W.L., Chen, Y., Zhou, L., Zeng, Z., Wang, C.P., An, L J., Hao, L.Y., Xu, G.L., Gao, X.D., Lou, M., Lv, J.Y. and Yang, Y.P. Overexpression of metastasis-associated in colon cancer predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. Wor.J. Gastro.2012; 18:2995-3003.
4 Ding, J., Jin, W., Chen, C., Shao, Z. and Wu, J. Tumor Associated Macrophage Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer. PLoS One. 2012;7:e41942.
5 Barar J. Targeting tumor microenvironment.the key role of immune system. Bioimpacts. 2012;2(1):1-3.
6 Hagemann T, Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol.2009;512:325-332.
7 Groot Kormelink T, Abudukelimu A, Redegeld FA.Mast cells as target in cancer therapy. Curr Pharm Des.2009; 15(16):1868-1878.
8 Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C.E., Schledzewski, K.and Goerdt,S. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Sca. J. Immunol. 2001;53:386-392.
9 Maniecki, M.B., Etzerodt, A., Ulh(?)i, B.P., Steiniche, T., Borre, M., Dyrskj(?)t, L., Orntoft,T.F., Moestrup, S.K. and M(?)ller, H.J. Tumor-promoting macrophages induce the expression of the macrophage-specific receptorCD163 in malignant cells. Int.J.Cancer. 2012; 131:2320-2331.
10 Yoon, D.H., Koh, Y.W., Kang, H.J., Kim, S., Park, C.S., Lee, S.W., Suh, C. and Huh, J. CD68 and CD163as prognostic factors for Korean patients with Hodgkin lymphoma. Eur. J. Haematol.2012;88:292-305.
11 Buechler C, Eisinger K, Krautbauer S. Diagnostic and Prognostic Potential of The Macrophage Specific Receptor CD 163 in Inflammatory Diseases. Inflamm Allergy Drug Targets.2013 Oct 3.
12 Kontny E, Prochorec-Sobieszek M. Articular adipose tissue resident macrophages in rheumatoid arthritis patients:potential contribution to local abnormalities. Rheumatology (Oxford).2013 Sep 6.
13 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. and Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012;18:1732-1744.
1 Moestrup, S.K. and M(?)ller, H.J. CD 163:a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med.2004;36:347-354.
2 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol 2011; 49:365-374.
3 Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD 163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol.2000;67:97-103.
4 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012 Jun; 14(6):914-936.
5 Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol.2009; 130:338-346.
6 Jens Haugbolle Thomsen, Anders Etzerodt, Pia Svendsen, and S(?)ren K. Moestrup. The Haptoglobin-CD163-Heme Oxygenase-1 Pathway for Hemoglobin Scavenging. Oxid Med Cell Longev.2013; 2013:523652.
7 Schaer DJ, Alayash AI, Buehler PW.Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD 163, a scavenger receptor. Antioxid Redox Signal.2007 Jul;9(7):991.
8 Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavengerreceptor superfamily. Eur J Immunol.1993; 23:2320-2325.
9 Ritter M, Buechler C, Langmann T, Schmitz G. Genomicorganization and chromosomal localization of the humanCD163 (M130) gene:a member of the scavenger receptor cysteine-rich superfamily. Biochem Biophys Res Comm.1999; 260:466-474.
10 Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol.2013 Jul 12; 14:1.
11 Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD 163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One. 2012;7(8):e43919.
12 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B,Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Arthritis Res Ther.2013 Jun 24;15(3):R69.
13 Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.A previously unrecognized protein-protein interaction between TWEAK and CD 163:potential biological implications J Immunol.2007 Jun 15;178(12):8183-8194.
14 Van den Heuvel MM, Tensen CP, Van As JH, et al. Regulation of CD 163 on human macrophages:cross-linking of CD 163 induces signaling and activation.J Leukoc Biol. 1999;66:858-866.
15 Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T. Acid glycoprotein up-regulates CD163 via TLR4/CD14 protein pathway:possible protection against hemolysis-induced oxidative stress.Komori H, Watanabe H, Shuto T, J Biol Chem.2012 Aug 31;287(36):30688-30700.
16 Brunialti MK, Santos MC, Rigato O, et al. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One.2012;7(5):e37393
17 Cui yun. The progressof the relationship between sCD163and Sepsis and severe infection.Pediatric emergency medicine in China.2011,18(4):175-177.
18 Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, M(?)ller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS.2006 Feb; 114(2):103-111.
19 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries.Indian J Plast Surg. 2011; 44:118-124.
20 Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev.2013; 2013: 523652.
21 Gu DN, Chen YP, Lu MQ. Role of CD163/HO-1 pathway in a rat acute liver failure model. Zhonghua Gan Zang Bing Za Zhi.2008 Dec; 16(12):944-945.
22 Liu XY, Hu JH, Wang HF.. Analysis of prognostic factors for patients with acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi.2009 Aug; 17(8): 607-610.
23 Longxiang Su, Lin Feng, Changting Liu, et al. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. BMC Nephrology. 2012,13:123-132.
24 Golbar HM, Izawa T, Juniantito V, Ichikawa C, Tanaka M, Kuwamura M, Yamate J Immunohistochemical characterization of macrophages and myofibroblasts in fibrotic liver lesions due to Fasciola infection in cattle. J Vet Med Sci.2013 Jul 31; 75(7): 857-865.
25 Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol.2013; 58(5):956-961.
26 Yang YY, Hou MC, Lin MW, Chen PH, Liao WC, Chu CJ, Lin HC. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients. J Gastroenterol Hepatol.2013; 28(1):112-121.
27 Gr(?)nbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, M(?)ller S..Soluble CD 163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther.2012;36(2):173-180.
28 Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol.2013; 19(30):4984-4991.
29 Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci.2013; 58(1):126-33.
30 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int.2012 Feb; 32(2):403-407.
31 Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC.Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS.2013 Jun 1;27(9):1387-1395.
32 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD 163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
33 Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, Monteleone I, Zorzi F, De Nitto D, Colantoni A, Biancone L, Pallone F, Monteleone G. Lesional Accumulation of CD163-Expressing Cell in the Gut of Patients with Inflammatory Bowel Disease. PLoS One.2013;8(7):e69839.
34 Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection:Results of Two International Observational Cohort Studies. Plos One.2013; 8(2):e57121.
35 Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis.2013; 26(5):413-419. 36 Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V,
Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology.2013; 2(3):e23562.
37 Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One.2013; 8(5):e63451.
38 Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K. Intra epithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immunity.2013;(13):1-7.
39 Bedewy M, El-Maghraby S, Bedewy A. CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res.2013 Jun; 48(2):121-127.
40 Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, Gomez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcfa de Herreros A, Casal I, Bonilla F, Pena C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci.2013; 104(4):437-444.
41 Cui YL, Li HK, Zhou HY,et al. Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac JCancer Prev.2013; 14(2):1003-1007.
42 Waidmann O, Koberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiβ M, Kronenberger B, Piiper A.. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol. 2013 Jun 17.
43 Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One.2013; 8(3):e59771.
44 Fjeldborg K, Christiansen T, Bennetzen M, J M Ller H, Pedersen SB, Richelsen BR.. The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss. Obesity (Silver Spring).2013 Mar 20.
45 Parkner T, Sorensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, Moller HJ. Soluble CD 163:a biomarker linking macrophages and insulin resistance. Diabetologia.2012 Jun;55(6):1856-1862.
46 Sonier B, Strom A, Wang GS, Patrick C, Crookshank JA, Mojibian M, MacFarlane AJ, Scott FW. Antibodies from a patient with type 1 diabetes and celiac disease bind to macrophages that express the scavenger receptor CD 163. Can J Gastroenterol.2011 Jun; 25(6):327-329.
47 Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, Wheatcroft SB, Ponnambalam S. Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease. Int J Hypertens.2010; 2010: 646929.
48 Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, M(?)ller HJ, Moestrup SK.l. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther.2012; 20(8):1550-1558.
49 Zhang N, Palmer AF. Liposomes surface conjugated with human hemoglobin target delivery to macrophages. Biotechnol Bioeng.2012; 109(3):823-829.
1 Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S. Variability in the precore and core promoter regions of HBV strains in morocco:characterization and impact on liver disease progression. PLoS One.2012; 7:e42891.
2 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liverfailure:Consensus recommendations of the Asian Pacific Associationfor the study of the liver (APASL). Hepatol Int.2009; 3:269-282.
3 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure:a prospective cohort study. Crit Care.2012 Nov 27;16(6):R227.
4 Wang LY, Meng QH, Zou ZQ, Fan YC, Han J, Qi ZX, Ge J, Xu AL, Wang SK, Wang K. Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure. Dig Dis Sci.2011; 57:667-674.
5 Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. Scientific World Journal.2011; 11:2391-2402.
6 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD 163 and its role in inflammation. Folia Histochem. Cytobiol.2011; 49:365-374.
7 Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure:a retrospective study. Mycoses.2013.
8 Zhao J, Zhang JY, Yu HW, He YL, Zhao JJ, Li J, Zhu YK, Yao QW, Wang JH, Liu HX, Shi SY, Zou ZS, Xu XS, Zhou CB, Wang FS, Meng QH. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol.2012 Sep;9(5):417-422.
9 Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, Zhao M. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett.2013; 149:41-49.
10 Li shanshan, Chen yu, Duan Zhongping. CD 163 and SCD163:the newmarker of the evaluation of liver failure. J Clin Hepatol.2011; 27(10):1112-1115.
11 Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer, Williams KC, Grinspoon S.F, Rosenberg ES. Soluble CD 163, a novel marker of activated macrophages, is elevatedand associated with noncaLCified coronary plaque in HIV 20-infected patients. J Infect Dis. 2011; 204:1227-1236.
12 Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD,van den Berg TK. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood.2009; 113:887-892.
13 Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J.1976; 115:1191-1192.
14 Etzerodt A, Maniecki MB, Graversen JH, M(?)ller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release.2012; 160:72-80.
15 Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One.2011;6:e19968.
16 Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther.2010; 12:R128.
17 He WP, Hu JH, Zhao J, Tong JJ, Ding JB, Lin F, Wang HF. Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure. Chin Med J (Engl).2012; 125:2272-2278.
18 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol.2011; 9:351-356.
19 M(?)ller HJ. Soluble CD163. Scand J Clin Lab Invest.2012; 72:1-13.
20 M(?)ller HJ, Gr(?)nbaek H, Schi(?)dt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007; 47:671-676.
21 Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol.2011; 714:141.
22 Onofre G, Kolackova M, Jankovicova K, Krejsekb J. Scavenger receptor CD 163 and its biological functions. ActaMedica (Hradec Kralove).2009; 52:57-61.
23 Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-Mac3:a new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936-945.
24 Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteines-rich family (CD163). J Immunol.1998;161:1883-1890.
25 Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine.2000;12;1312-1321.
26 Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples:influence of different anticoagulants. Clin Vaccin Immunol. 2006; 13:704-707.
27 Davis BH, Zarev PV. Human monocyte CD 163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom.2005; 63:16-22.
28 Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocye hemoglobin scavenger receptor CD163. J Leukoc Biol.2002; 72:711-717.
29 Weaver LK, Pioli PA, Wardwell K, Vogel SN,Guyre PM. Up-regulation of human monocyte CD 163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol.2007; 81:663-671.
30 Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Sakai K, Inoue Y, Ihn H.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol.2012 Jul-Aug; 22(4):512-517.
31 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012; 14:914-936.
32 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD 163:A novel biomarker for the susceptibility to sepsis in severe burn injuries. Indian J Plast Surg. 2011; 44:118-124.
33 Holger Jon M(?)ller, MD PhD, Henning Gr(?)nbaek, MD PhD, Frank V. Schi(?)dt, MD PhD, Peter Holland-Fischer, MD, Michael Schilsky, MD, Santiago Munoz, MD, Tarek Hassanein, MD, and William M. Lee, MD, the US Acute Liver Failure Study Group. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007 November; 47(5):671-676.
34 Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD 163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. InfectDis.2011; 204:154-163.
35 Jude C, Samasca G, Balacescu L, Balacescu L, Blacescu O. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int.2012.
36 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and Fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
37 Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD 163 (sCD163) in Sepsis, a Prospective Study. PLoS One.2012; 7:e38400.
38 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. & Powell, E.E. Macrophage secretory products induce an inflammatory phenotype inhepatocytes. Wor.J.Gastro.2012;18:1732-1744.
39 Kazankov K, Barrera F, Moller HJ. Soluble CD163, a macrophage activation marker,is independently associated with fibrosis in patients with chronic hepatitis C and B. Hepatology.2014; March 13.
40 Wu hui-ling. The effect of endotoxemia on scavenger receptor CD 163 in chronic on acute liver failure. [D]. Wuhan, HuaZhong TechnologyMedical school.2010.
41 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol.2012; 18:4604-4609.
42 Lai J, Li XJ, Zhang SQ, Xu QH, Zhu JY, Ke WM. The relationship of HBeAg status with HBV DNA loads, MELD scores in patients with acute-on-chronic hepatitis B liver failure during terminal phases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26:51-53.
43 Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol.2012; 27: 223-230.
44 Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F, Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. Viral Hepat.2010 Dec;17(12):887-895.
45 Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005;201(5):379-384.
1 Su L, Feng L, Liu C, Jiang Z, Li M, Xiao K, Yan P, Jia Y, Feng D, Xie L. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. Rheumatol Int.2012; 13:123.
2 Ingels C, M(?)ller HJ, Hansen TK, Wouters PJ, Vanhorebeek I, Van den Berghe G. Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients. J Clin Immunol.2013; 33:619-629.
3 Qu, J.H., Chang, X.J., Lu,Y.Y., Bai, W.L., Chen, Y., Zhou, L., Zeng, Z., Wang, C.P., An, L.J., Hao, L.Y., Xu, G.L., Gao, X.D., Lou, M., Lv, J.Y. and Yang, Y.P. Overexpression of metastasis-associated in colon cancer predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. Wor.J. Gastro.2012; 18:2995-3003.
4 Ding, J., Jin, W., Chen, C., Shao, Z. and Wu, J. Tumor Associated Macrophage Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer. PLoS One.2012;7:e41942.
5 Barar J. Targeting tumor microenvironment:the key role of immune system. Bioimpacts. 2012;2(1):1-3.
6 Hagemann T, Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol.2009;512:325-332.
7 Groot Kormelink T, Abudukelimu A, Redegeld FA.Mast cells as target in cancer therapy. Curr Pharm Des.2009; 15(16):1868-1878.
8 Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C.E., Schledzewski, K.and Goerdt,S. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Sca. J. Immunol. 2001;53:386-392.
9 Maniecki, M.B., Etzerodt, A., Ulhoi, B.P., Steiniche, T., Borre, M., Dyrskj(?)t, L., Orntoft,T.F., Moestrup, S.K. and M(?)ller, H.J. Tumor-promoting macrophages induce the expression of the macrophage-specific receptorCD163 in malignant cells. Int.J.Cancer. 2012;131:2320-2331.
10 Yoon, D.H., Koh, Y.W., Kang, H.J., Kim, S., Park, C.S., Lee, S.W., Suh, C. and Huh, J. CD68 and CD163as prognostic factors for Korean patients with Hodgkin lymphoma. Eur. J. Haematol.2012;88:292-305.
11 Buechler C, Eisinger K, Krautbauer S. Diagnostic and Prognostic Potential of The Macrophage Specific Receptor CD 163 in Inflammatory Diseases. Inflamm Allergy Drug Targets.2013 Oct 3.
12 Kontny E, Prochorec-Sobieszek M. Articular adipose tissue resident macrophages in rheumatoid arthritis patients:potential contribution to local abnormalities. Rheumatology (Oxford).2013 Sep 6.
13 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. and Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012; 18:1732-1744.
1 Moestrup, S.K. and M(?)oller, H.J. CD 163:a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med.2004;36:347-354.
2 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol 2011; 49:365-374.
3 Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of sca2enger receptor CD 163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol.2000;67:97-103.
4 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012 Jun; 14(6):914-936.
5 Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol.2009; 130:338-346.
6 Jens Haugb(?)lle Thomsen, Anders Etzerodt, Pia Svendsen, and S(?)ren K. Moestrup. The Haptoglobin-CD163-Heme Oxygenase-1 Pathway for Hemoglobin Scavenging. Oxid Med Cell Longev.2013; 2013:523652.
7 Schaer DJ, Alayash AI, Buehler PW.Gating the radical hemoglobin to macrophages:the anti-inflammatory role of CD163, a scavenger receptor. Antioxid Redox Signal.2007 Jul;9(7):991.
8 Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavengerreceptor superfamily. Eur J Immunol.1993; 23:2320-2325.
9 Ritter M, Buechler C, Langmann T, Schmitz G. Genomicorganization and chromosomal localization of the humanCD163 (M130) gene:a member of the scavenger receptor cysteine-rich superfamily. Biochem Biophys Res Comm.1999; 260:466-474.
10 Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol.2013 Jul 12;14:1.
11 Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One. 2012;7(8):e43919.
12 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Arthritis Res Ther.2013 Jun 24;15(3):R69.
13 Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.A previously unrecognized protein-protein interaction between TWEAK and CD 163:potential biological implications J Immunol.2007 Jun 15; 178(12):8183-8194.
14 Van den Heuvel MM, Tensen CP, Van As JH, et al. Regulation of CD 163 on human macrophages:cross-linking of CD163 induces signaling and activation.J Leukoc Biol. 1999;66:858-866.
15 Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T. Acid glycoprotein up-regulates CD 163 via TLR4/CD14 protein pathway:possible protection against hemolysis-induced oxidative stress.Komori H, Watanabe H, Shuto T, J Biol Chem.2012 Aug 31;287(36):30688-30700.
16 Brunialti MK, Santos MC, Rigato O, et al. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One.2012;7(5):e37393
17 Cui yun. The progressof the relationship between sCD163and Sepsis and severe infection.Pediatric emergency medicine in China.2011,18(4):175-177.
18 Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, M(?)ller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS.2006 Feb; 114(2):103-111.
19 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries.Indian J Plast Surg. 2011;44:118-124.
20 Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev.2013; 2013: 523652.
21 Gu DN, Chen YP, Lu MQ. Role of CD163/HO-1 pathway in a rat acute liver failure model. Zhonghua Gan Zang Bing Za Zhi.2008 Dec; 16(12):944-945.
22 Liu XY, Hu JH, Wang HF.. Analysis of prognostic factors for patients with acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi.2009 Aug; 17(8): 607-610.
23 Longxiang Su, Lin Feng, Changting Liu, et al. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. BMC Nephrology. 2012,13:123-132.
24 Golbar HM, Izawa T, Juniantito V, Ichikawa C, Tanaka M, Kuwamura M, Yamate J. Immunohistochemical characterization of macrophages and myofibroblasts in fibrotic liver lesions due to Fasciola infection in cattle. J Vet Med Sci.2013 Jul 31; 75(7): 857-865.
25 Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol.2013; 58(5):956-961.
26 Yang YY, Hou MC, Lin MW, Chen PH, Liao WC, Chu CJ, Lin HC. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients. J Gastroenterol Hepatol.2013; 28(1):112-121.
27 Granbaek H, Sandahl TD, Mortensen C, Vilstrup H, M(?)ller HJ, M(?)ller S..Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther.2012;36(2):173-180.
28 Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol.2013;19(30):4984-4991.
29 Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O.Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci.2013; 58(1):126-33.
30 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. Serum levels of soluble CD 163 in patients with systemic sclerosis. Rheumatol Int.2012 Feb; 32(2):403-407.
31 Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC.Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS.2013 Jun 1;27(9):1387-1395.
32 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD 163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
33 Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, Monteleone I, Zorzi F, De Nitto D, Colantoni A, Biancone L, Pallone F, Monteleone G. Lesional Accumulation of CD163-Expressing Cell in the Gut of Patients with Inflammatory Bowel Disease. PLoS One.2013;8(7):e69839.
34 Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection:Results of Two International Observational Cohort Studies. Plos One.2013,8(2), e57121.
35 Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis.2013; 26(5):413-419.
36 Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology.2013; 2(3):e23562.
37 Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One.2013 7; 8(5):e63451.
38 Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K. Intra epithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immunity.2013;(13):1-7.
39 Bedewy M, El-Maghraby S, Bedewy A. CD 163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res.2013 Jun; 48(2):121-127.
40 Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, G6mez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcia de Herreros A, Casal I, Bonilla F, Pena C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci.2013; 104(4):437-444.
41 Cui YL, Li HK, Zhou HY,et al. Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac JCancer Prev.2013; 14(2):1003-1007.
42 Waidmann O, Koberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiβ M, Kronenberger B, Piiper A.. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol. 2013 Jun 17.
43.Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD 163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One.2013; 8(3):e59771.
44 Fjeldborg K, Christiansen T, Bennetzen M, J M Ller H, Pedersen SB, Richelsen BR.. The Macrophage-Specific Serum Marker, Soluble CD 163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss. Obesity (Silver Spring).2013 Mar 20.
45 Parkner T, S(?)rensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, M(?)ller HJ. Soluble CD 163:a biomarker linking macrophages and insulin resistance. Diabetologia.2012 Jun;55(6):1856-1862.
46 Sonier B, Strom A, Wang GS, Patrick C, Crookshank JA, Mojibian M, MacFarlane AJ, Scott FW. Antibodies from a patient with type 1 diabetes and celiac disease bind to macrophages that express the scavenger receptor CD 163. Can J Gastroenterol.2011 Jun; 25(6):327-329.
47 Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, Wheatcroft SB, Ponnambalam S. Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease. Int J Hypertens.2010; 2010:646929.
48 Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Moller HJ, Moestrup SK.1. Targeting the hemoglobin scavenger receptor CD 163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther.2012; 20(8):1550-1558.
49 Zhang N, Palmer AF. Liposomes surface conjugated with human hemoglobin target delivery to macrophages. Biotechnol Bioeng.2012; 109(3):823-829.
2 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liverfailure:Consensus recommendations of the Asian Pacific Associationfor the study of the liver (APASL). Hepatol Int.2009; 3:269-282.
3 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure:a prospective cohort study. Crit Care.2012 Nov 27;16(6):R227.
4 Wang LY, Meng QH, Zou ZQ, Fan YC, Han J, Qi ZX, Ge J, Xu AL, Wang SK, Wang K. Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure. Dig Dis Sci.2011; 57:667-674.
5 Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. Scientific World Journal.2011; 11:2391-2402.
6 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol.2011; 49:365-374.
7 Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure:a retrospective study. Mycoses.2013.
8 Zhao J, Zhang JY, Yu HW, He YL, Zhao JJ, Li J, Zhu YK, Yao QW, Wang JH, Liu HX, Shi SY, Zou ZS, Xu XS, Zhou CB, Wang FS, Meng QH. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol.2012 Sep;9(5):417-422.
9 Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, Zhao M. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett.2013; 149:41-49.
10 Li shanshan, Chen yu, DuanZhongping. CD 163 and SCD163:the newmarker of the evaluation of liver failure. J Clin Hepatol.2011; 27(10):1112-1115.
11 Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer, Williams KC, Grinspoon S.F, Rosenberg ES. Soluble CD 163, a novel marker of activated macrophages, is elevatedand associated with noncaLCified coronary plaque in HIV 20-infected patients. J Infect Dis. 2011; 204:1227-1236.
12 Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD,van den Berg TK. The macrophage scavenger receptor CD 163 functions as an innate immune sensor for bacteria. Blood.2009; 113:887-892.
13 Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J.1976; 115:1191-1192.
14 Etzerodt A, Maniecki MB, Graversen JH, M(?)ller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD 163. J Control Release.2012; 160:72-80.
15 Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD 163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One.2011; 6:e19968.
16 Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther.2010; 12:R128.
17 He WP, Hu JH, Zhao J, Tong JJ, Ding JB, Lin F, Wang HF. Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure. Chin Med J (Engl).2012; 125:2272-2278.
18 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol.2011; 9:351-356.
19 M(?)ller HJ. Soluble CD163. Scand J Clin Lab Invest.2012; 72:1-13.
20 M(?)ller HJ, Gr(?)nbaek H, Schi(?)dt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007; 47:671-676.
21 Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol.2011; 714:141.
22 Onofre G, Kolackova M, Jankovicova K, Krejsekb J. Scavenger receptor CD163 and its biological functions. ActaMedica (Hradec Kralove).2009; 52:57-61.
23 Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-Mac3:a new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936-945.
24 Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteines-rich family (CD163). J Immunol.1998; 161:1883-1890.
25 Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine.2000;12:1312-1321.
26 Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples:influence of different anticoagulants. Clin Vaccin Immunol. 2006;13:704-707.
27 Davis BH, Zarev PV. Human monocyte CD 163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom.2005; 63:16-22.
28 Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocye hemoglobin scavenger receptor CD163. J Leukoc Biol.2002; 72:711-717.
29 Weaver LK, Pioli PA, Wardwell K, Vogel SN,Guyre PM. Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol.2007; 81:663-671.
30 Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Sakai K, Inoue Y, Ihn H.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol.2012 Jul-Aug; 22(4):512-517.
31 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012; 14:914-936.
32 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries. Indian J Plast Surg. 2011; 44:118-124.
33 Holger Jon M(?)ller, MD PhD, Henning Gr(?)naek, MD PhD, Frank V. Schi(?)dt, MD PhD, PeterHol land-Fischer, MD, Michael Schilsky, MD, Santiago Munoz, MD, Tarek Hassanein, MD, and William M. Lee, MD, the US Acute Liver Failure Study Group. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007 November; 47(5):671-676.
34 Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. InfectDis.2011; 204:154-163.
35 Jude C, Samasca G, Balacescu L, Balacescu L, Blacescu O. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int.2012.
36 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and Fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
37 Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study. PLoS One.2012; 7:e38400.
38 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. & Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012;18:1732-1744.
39 Kazankov K,Barrera F,Moller HJ. Soluble CD163,a macrophage activation marker,is independently associated with fibrosis in patients with chronic hepatitis C and B. Hepatology.2014; March 13.
40 Wu hui-ling. The effect of endotoxemia on scavenger receptor CD163 in chronic on acute liver failure. [D]. Wuhan, HuaZhong TechnologyMedical school.2010.
41 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol.2012; 18:4604-4609.
42 Lai J, Li XJ, Zhang SQ, Xu QH, Zhu JY, Ke WM. The relationship of HBeAg status with HBV DNA loads, MELD scores in patients with acute-on-chronic hepatitis B liver failure during terminal phases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26:51-53.
43 Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol.2012; 27: 223-230.
44 Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F, Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. Viral Hepat.2010 Dec;17(12):887-895.
45 Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD 163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005;201(5):379-384.
1 Su L, Feng L, Liu C, Jiang Z, Li M, Xiao K, Yan P, Jia Y, Feng D, Xie L. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. Rheumatol Int.2012; 13:123.
2 Ingels C, M(?)ller HJ, Hansen TK, Wouters PJ, Vanhorebeek I, Van den Berghe G. Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients. J Clin Immunol.2013; 33:619-629.
3 Qu, J.H., Chang, X.J., Lu,Y.Y., Bai, W.L., Chen, Y., Zhou, L., Zeng, Z., Wang, C.P., An, L J., Hao, L.Y., Xu, G.L., Gao, X.D., Lou, M., Lv, J.Y. and Yang, Y.P. Overexpression of metastasis-associated in colon cancer predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. Wor.J. Gastro.2012; 18:2995-3003.
4 Ding, J., Jin, W., Chen, C., Shao, Z. and Wu, J. Tumor Associated Macrophage Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer. PLoS One. 2012;7:e41942.
5 Barar J. Targeting tumor microenvironment.the key role of immune system. Bioimpacts. 2012;2(1):1-3.
6 Hagemann T, Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol.2009;512:325-332.
7 Groot Kormelink T, Abudukelimu A, Redegeld FA.Mast cells as target in cancer therapy. Curr Pharm Des.2009; 15(16):1868-1878.
8 Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C.E., Schledzewski, K.and Goerdt,S. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Sca. J. Immunol. 2001;53:386-392.
9 Maniecki, M.B., Etzerodt, A., Ulh(?)i, B.P., Steiniche, T., Borre, M., Dyrskj(?)t, L., Orntoft,T.F., Moestrup, S.K. and M(?)ller, H.J. Tumor-promoting macrophages induce the expression of the macrophage-specific receptorCD163 in malignant cells. Int.J.Cancer. 2012; 131:2320-2331.
10 Yoon, D.H., Koh, Y.W., Kang, H.J., Kim, S., Park, C.S., Lee, S.W., Suh, C. and Huh, J. CD68 and CD163as prognostic factors for Korean patients with Hodgkin lymphoma. Eur. J. Haematol.2012;88:292-305.
11 Buechler C, Eisinger K, Krautbauer S. Diagnostic and Prognostic Potential of The Macrophage Specific Receptor CD 163 in Inflammatory Diseases. Inflamm Allergy Drug Targets.2013 Oct 3.
12 Kontny E, Prochorec-Sobieszek M. Articular adipose tissue resident macrophages in rheumatoid arthritis patients:potential contribution to local abnormalities. Rheumatology (Oxford).2013 Sep 6.
13 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. and Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012;18:1732-1744.
1 Moestrup, S.K. and M(?)ller, H.J. CD 163:a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med.2004;36:347-354.
2 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol 2011; 49:365-374.
3 Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD 163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol.2000;67:97-103.
4 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012 Jun; 14(6):914-936.
5 Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol.2009; 130:338-346.
6 Jens Haugbolle Thomsen, Anders Etzerodt, Pia Svendsen, and S(?)ren K. Moestrup. The Haptoglobin-CD163-Heme Oxygenase-1 Pathway for Hemoglobin Scavenging. Oxid Med Cell Longev.2013; 2013:523652.
7 Schaer DJ, Alayash AI, Buehler PW.Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD 163, a scavenger receptor. Antioxid Redox Signal.2007 Jul;9(7):991.
8 Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavengerreceptor superfamily. Eur J Immunol.1993; 23:2320-2325.
9 Ritter M, Buechler C, Langmann T, Schmitz G. Genomicorganization and chromosomal localization of the humanCD163 (M130) gene:a member of the scavenger receptor cysteine-rich superfamily. Biochem Biophys Res Comm.1999; 260:466-474.
10 Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol.2013 Jul 12; 14:1.
11 Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD 163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One. 2012;7(8):e43919.
12 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B,Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Arthritis Res Ther.2013 Jun 24;15(3):R69.
13 Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.A previously unrecognized protein-protein interaction between TWEAK and CD 163:potential biological implications J Immunol.2007 Jun 15;178(12):8183-8194.
14 Van den Heuvel MM, Tensen CP, Van As JH, et al. Regulation of CD 163 on human macrophages:cross-linking of CD 163 induces signaling and activation.J Leukoc Biol. 1999;66:858-866.
15 Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T. Acid glycoprotein up-regulates CD163 via TLR4/CD14 protein pathway:possible protection against hemolysis-induced oxidative stress.Komori H, Watanabe H, Shuto T, J Biol Chem.2012 Aug 31;287(36):30688-30700.
16 Brunialti MK, Santos MC, Rigato O, et al. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One.2012;7(5):e37393
17 Cui yun. The progressof the relationship between sCD163and Sepsis and severe infection.Pediatric emergency medicine in China.2011,18(4):175-177.
18 Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, M(?)ller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS.2006 Feb; 114(2):103-111.
19 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries.Indian J Plast Surg. 2011; 44:118-124.
20 Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev.2013; 2013: 523652.
21 Gu DN, Chen YP, Lu MQ. Role of CD163/HO-1 pathway in a rat acute liver failure model. Zhonghua Gan Zang Bing Za Zhi.2008 Dec; 16(12):944-945.
22 Liu XY, Hu JH, Wang HF.. Analysis of prognostic factors for patients with acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi.2009 Aug; 17(8): 607-610.
23 Longxiang Su, Lin Feng, Changting Liu, et al. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. BMC Nephrology. 2012,13:123-132.
24 Golbar HM, Izawa T, Juniantito V, Ichikawa C, Tanaka M, Kuwamura M, Yamate J Immunohistochemical characterization of macrophages and myofibroblasts in fibrotic liver lesions due to Fasciola infection in cattle. J Vet Med Sci.2013 Jul 31; 75(7): 857-865.
25 Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol.2013; 58(5):956-961.
26 Yang YY, Hou MC, Lin MW, Chen PH, Liao WC, Chu CJ, Lin HC. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients. J Gastroenterol Hepatol.2013; 28(1):112-121.
27 Gr(?)nbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, M(?)ller S..Soluble CD 163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther.2012;36(2):173-180.
28 Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol.2013; 19(30):4984-4991.
29 Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci.2013; 58(1):126-33.
30 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int.2012 Feb; 32(2):403-407.
31 Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC.Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS.2013 Jun 1;27(9):1387-1395.
32 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD 163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
33 Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, Monteleone I, Zorzi F, De Nitto D, Colantoni A, Biancone L, Pallone F, Monteleone G. Lesional Accumulation of CD163-Expressing Cell in the Gut of Patients with Inflammatory Bowel Disease. PLoS One.2013;8(7):e69839.
34 Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection:Results of Two International Observational Cohort Studies. Plos One.2013; 8(2):e57121.
35 Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis.2013; 26(5):413-419. 36 Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V,
Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology.2013; 2(3):e23562.
37 Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One.2013; 8(5):e63451.
38 Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K. Intra epithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immunity.2013;(13):1-7.
39 Bedewy M, El-Maghraby S, Bedewy A. CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res.2013 Jun; 48(2):121-127.
40 Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, Gomez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcfa de Herreros A, Casal I, Bonilla F, Pena C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci.2013; 104(4):437-444.
41 Cui YL, Li HK, Zhou HY,et al. Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac JCancer Prev.2013; 14(2):1003-1007.
42 Waidmann O, Koberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiβ M, Kronenberger B, Piiper A.. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol. 2013 Jun 17.
43 Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One.2013; 8(3):e59771.
44 Fjeldborg K, Christiansen T, Bennetzen M, J M Ller H, Pedersen SB, Richelsen BR.. The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss. Obesity (Silver Spring).2013 Mar 20.
45 Parkner T, Sorensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, Moller HJ. Soluble CD 163:a biomarker linking macrophages and insulin resistance. Diabetologia.2012 Jun;55(6):1856-1862.
46 Sonier B, Strom A, Wang GS, Patrick C, Crookshank JA, Mojibian M, MacFarlane AJ, Scott FW. Antibodies from a patient with type 1 diabetes and celiac disease bind to macrophages that express the scavenger receptor CD 163. Can J Gastroenterol.2011 Jun; 25(6):327-329.
47 Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, Wheatcroft SB, Ponnambalam S. Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease. Int J Hypertens.2010; 2010: 646929.
48 Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, M(?)ller HJ, Moestrup SK.l. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther.2012; 20(8):1550-1558.
49 Zhang N, Palmer AF. Liposomes surface conjugated with human hemoglobin target delivery to macrophages. Biotechnol Bioeng.2012; 109(3):823-829.
1 Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S. Variability in the precore and core promoter regions of HBV strains in morocco:characterization and impact on liver disease progression. PLoS One.2012; 7:e42891.
2 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liverfailure:Consensus recommendations of the Asian Pacific Associationfor the study of the liver (APASL). Hepatol Int.2009; 3:269-282.
3 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure:a prospective cohort study. Crit Care.2012 Nov 27;16(6):R227.
4 Wang LY, Meng QH, Zou ZQ, Fan YC, Han J, Qi ZX, Ge J, Xu AL, Wang SK, Wang K. Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure. Dig Dis Sci.2011; 57:667-674.
5 Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. Scientific World Journal.2011; 11:2391-2402.
6 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD 163 and its role in inflammation. Folia Histochem. Cytobiol.2011; 49:365-374.
7 Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure:a retrospective study. Mycoses.2013.
8 Zhao J, Zhang JY, Yu HW, He YL, Zhao JJ, Li J, Zhu YK, Yao QW, Wang JH, Liu HX, Shi SY, Zou ZS, Xu XS, Zhou CB, Wang FS, Meng QH. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol.2012 Sep;9(5):417-422.
9 Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, Zhao M. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett.2013; 149:41-49.
10 Li shanshan, Chen yu, Duan Zhongping. CD 163 and SCD163:the newmarker of the evaluation of liver failure. J Clin Hepatol.2011; 27(10):1112-1115.
11 Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer, Williams KC, Grinspoon S.F, Rosenberg ES. Soluble CD 163, a novel marker of activated macrophages, is elevatedand associated with noncaLCified coronary plaque in HIV 20-infected patients. J Infect Dis. 2011; 204:1227-1236.
12 Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD,van den Berg TK. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood.2009; 113:887-892.
13 Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J.1976; 115:1191-1192.
14 Etzerodt A, Maniecki MB, Graversen JH, M(?)ller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release.2012; 160:72-80.
15 Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One.2011;6:e19968.
16 Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther.2010; 12:R128.
17 He WP, Hu JH, Zhao J, Tong JJ, Ding JB, Lin F, Wang HF. Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure. Chin Med J (Engl).2012; 125:2272-2278.
18 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol.2011; 9:351-356.
19 M(?)ller HJ. Soluble CD163. Scand J Clin Lab Invest.2012; 72:1-13.
20 M(?)ller HJ, Gr(?)nbaek H, Schi(?)dt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007; 47:671-676.
21 Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol.2011; 714:141.
22 Onofre G, Kolackova M, Jankovicova K, Krejsekb J. Scavenger receptor CD 163 and its biological functions. ActaMedica (Hradec Kralove).2009; 52:57-61.
23 Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-Mac3:a new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936-945.
24 Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteines-rich family (CD163). J Immunol.1998;161:1883-1890.
25 Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine.2000;12;1312-1321.
26 Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples:influence of different anticoagulants. Clin Vaccin Immunol. 2006; 13:704-707.
27 Davis BH, Zarev PV. Human monocyte CD 163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom.2005; 63:16-22.
28 Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocye hemoglobin scavenger receptor CD163. J Leukoc Biol.2002; 72:711-717.
29 Weaver LK, Pioli PA, Wardwell K, Vogel SN,Guyre PM. Up-regulation of human monocyte CD 163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol.2007; 81:663-671.
30 Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Sakai K, Inoue Y, Ihn H.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol.2012 Jul-Aug; 22(4):512-517.
31 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012; 14:914-936.
32 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD 163:A novel biomarker for the susceptibility to sepsis in severe burn injuries. Indian J Plast Surg. 2011; 44:118-124.
33 Holger Jon M(?)ller, MD PhD, Henning Gr(?)nbaek, MD PhD, Frank V. Schi(?)dt, MD PhD, Peter Holland-Fischer, MD, Michael Schilsky, MD, Santiago Munoz, MD, Tarek Hassanein, MD, and William M. Lee, MD, the US Acute Liver Failure Study Group. Soluble CD 163 from activated macrophages predicts mortality in acute liver failure. J Hepatol.2007 November; 47(5):671-676.
34 Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD 163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. InfectDis.2011; 204:154-163.
35 Jude C, Samasca G, Balacescu L, Balacescu L, Blacescu O. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int.2012.
36 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and Fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
37 Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD 163 (sCD163) in Sepsis, a Prospective Study. PLoS One.2012; 7:e38400.
38 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. & Powell, E.E. Macrophage secretory products induce an inflammatory phenotype inhepatocytes. Wor.J.Gastro.2012;18:1732-1744.
39 Kazankov K, Barrera F, Moller HJ. Soluble CD163, a macrophage activation marker,is independently associated with fibrosis in patients with chronic hepatitis C and B. Hepatology.2014; March 13.
40 Wu hui-ling. The effect of endotoxemia on scavenger receptor CD 163 in chronic on acute liver failure. [D]. Wuhan, HuaZhong TechnologyMedical school.2010.
41 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol.2012; 18:4604-4609.
42 Lai J, Li XJ, Zhang SQ, Xu QH, Zhu JY, Ke WM. The relationship of HBeAg status with HBV DNA loads, MELD scores in patients with acute-on-chronic hepatitis B liver failure during terminal phases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26:51-53.
43 Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol.2012; 27: 223-230.
44 Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F, Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. Viral Hepat.2010 Dec;17(12):887-895.
45 Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005;201(5):379-384.
1 Su L, Feng L, Liu C, Jiang Z, Li M, Xiao K, Yan P, Jia Y, Feng D, Xie L. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. Rheumatol Int.2012; 13:123.
2 Ingels C, M(?)ller HJ, Hansen TK, Wouters PJ, Vanhorebeek I, Van den Berghe G. Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients. J Clin Immunol.2013; 33:619-629.
3 Qu, J.H., Chang, X.J., Lu,Y.Y., Bai, W.L., Chen, Y., Zhou, L., Zeng, Z., Wang, C.P., An, L.J., Hao, L.Y., Xu, G.L., Gao, X.D., Lou, M., Lv, J.Y. and Yang, Y.P. Overexpression of metastasis-associated in colon cancer predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. Wor.J. Gastro.2012; 18:2995-3003.
4 Ding, J., Jin, W., Chen, C., Shao, Z. and Wu, J. Tumor Associated Macrophage Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer. PLoS One.2012;7:e41942.
5 Barar J. Targeting tumor microenvironment:the key role of immune system. Bioimpacts. 2012;2(1):1-3.
6 Hagemann T, Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol.2009;512:325-332.
7 Groot Kormelink T, Abudukelimu A, Redegeld FA.Mast cells as target in cancer therapy. Curr Pharm Des.2009; 15(16):1868-1878.
8 Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C.E., Schledzewski, K.and Goerdt,S. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Sca. J. Immunol. 2001;53:386-392.
9 Maniecki, M.B., Etzerodt, A., Ulhoi, B.P., Steiniche, T., Borre, M., Dyrskj(?)t, L., Orntoft,T.F., Moestrup, S.K. and M(?)ller, H.J. Tumor-promoting macrophages induce the expression of the macrophage-specific receptorCD163 in malignant cells. Int.J.Cancer. 2012;131:2320-2331.
10 Yoon, D.H., Koh, Y.W., Kang, H.J., Kim, S., Park, C.S., Lee, S.W., Suh, C. and Huh, J. CD68 and CD163as prognostic factors for Korean patients with Hodgkin lymphoma. Eur. J. Haematol.2012;88:292-305.
11 Buechler C, Eisinger K, Krautbauer S. Diagnostic and Prognostic Potential of The Macrophage Specific Receptor CD 163 in Inflammatory Diseases. Inflamm Allergy Drug Targets.2013 Oct 3.
12 Kontny E, Prochorec-Sobieszek M. Articular adipose tissue resident macrophages in rheumatoid arthritis patients:potential contribution to local abnormalities. Rheumatology (Oxford).2013 Sep 6.
13 Melino, M., Gadd, V.L., Walker, G.V., Skoien, R., Barrie, H.D., Jothimani, D., Horsfall, L., Jones, A., Sweet, M.J., Thomas, G.P., Clouston, A.D., Jonsson, J.R. and Powell, E.E. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Wor.J.Gastro.2012; 18:1732-1744.
1 Moestrup, S.K. and M(?)oller, H.J. CD 163:a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med.2004;36:347-354.
2 Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka, O. CD163 and its role in inflammation. Folia Histochem. Cytobiol 2011; 49:365-374.
3 Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of sca2enger receptor CD 163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol.2000;67:97-103.
4 Kneidl J, Loffler B, Erat MC, Kalinka J, Peters G, Roth J, Barczyk K. Soluble CD 163 promotes recognition, phagocytosis and killing of Staphylococcus aureus via binding of specific fibronectin peptides. Cell Microbiol.2012 Jun; 14(6):914-936.
5 Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol.2009; 130:338-346.
6 Jens Haugb(?)lle Thomsen, Anders Etzerodt, Pia Svendsen, and S(?)ren K. Moestrup. The Haptoglobin-CD163-Heme Oxygenase-1 Pathway for Hemoglobin Scavenging. Oxid Med Cell Longev.2013; 2013:523652.
7 Schaer DJ, Alayash AI, Buehler PW.Gating the radical hemoglobin to macrophages:the anti-inflammatory role of CD163, a scavenger receptor. Antioxid Redox Signal.2007 Jul;9(7):991.
8 Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavengerreceptor superfamily. Eur J Immunol.1993; 23:2320-2325.
9 Ritter M, Buechler C, Langmann T, Schmitz G. Genomicorganization and chromosomal localization of the humanCD163 (M130) gene:a member of the scavenger receptor cysteine-rich superfamily. Biochem Biophys Res Comm.1999; 260:466-474.
10 Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol.2013 Jul 12;14:1.
11 Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One. 2012;7(8):e43919.
12 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Arthritis Res Ther.2013 Jun 24;15(3):R69.
13 Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.A previously unrecognized protein-protein interaction between TWEAK and CD 163:potential biological implications J Immunol.2007 Jun 15; 178(12):8183-8194.
14 Van den Heuvel MM, Tensen CP, Van As JH, et al. Regulation of CD 163 on human macrophages:cross-linking of CD163 induces signaling and activation.J Leukoc Biol. 1999;66:858-866.
15 Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T. Acid glycoprotein up-regulates CD 163 via TLR4/CD14 protein pathway:possible protection against hemolysis-induced oxidative stress.Komori H, Watanabe H, Shuto T, J Biol Chem.2012 Aug 31;287(36):30688-30700.
16 Brunialti MK, Santos MC, Rigato O, et al. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One.2012;7(5):e37393
17 Cui yun. The progressof the relationship between sCD163and Sepsis and severe infection.Pediatric emergency medicine in China.2011,18(4):175-177.
18 Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, M(?)ller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS.2006 Feb; 114(2):103-111.
19 Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163:A novel biomarker for the susceptibility to sepsis in severe burn injuries.Indian J Plast Surg. 2011;44:118-124.
20 Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev.2013; 2013: 523652.
21 Gu DN, Chen YP, Lu MQ. Role of CD163/HO-1 pathway in a rat acute liver failure model. Zhonghua Gan Zang Bing Za Zhi.2008 Dec; 16(12):944-945.
22 Liu XY, Hu JH, Wang HF.. Analysis of prognostic factors for patients with acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi.2009 Aug; 17(8): 607-610.
23 Longxiang Su, Lin Feng, Changting Liu, et al. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury:a prospective study. BMC Nephrology. 2012,13:123-132.
24 Golbar HM, Izawa T, Juniantito V, Ichikawa C, Tanaka M, Kuwamura M, Yamate J. Immunohistochemical characterization of macrophages and myofibroblasts in fibrotic liver lesions due to Fasciola infection in cattle. J Vet Med Sci.2013 Jul 31; 75(7): 857-865.
25 Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol.2013; 58(5):956-961.
26 Yang YY, Hou MC, Lin MW, Chen PH, Liao WC, Chu CJ, Lin HC. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients. J Gastroenterol Hepatol.2013; 28(1):112-121.
27 Granbaek H, Sandahl TD, Mortensen C, Vilstrup H, M(?)ller HJ, M(?)ller S..Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther.2012;36(2):173-180.
28 Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol.2013;19(30):4984-4991.
29 Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O.Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci.2013; 58(1):126-33.
30 Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K. Serum levels of soluble CD 163 in patients with systemic sclerosis. Rheumatol Int.2012 Feb; 32(2):403-407.
31 Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC.Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS.2013 Jun 1;27(9):1387-1395.
32 Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD 163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD 163 by TIMP-3. Clin Exp Immunol.2002; 130:156-161.
33 Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, Monteleone I, Zorzi F, De Nitto D, Colantoni A, Biancone L, Pallone F, Monteleone G. Lesional Accumulation of CD163-Expressing Cell in the Gut of Patients with Inflammatory Bowel Disease. PLoS One.2013;8(7):e69839.
34 Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection:Results of Two International Observational Cohort Studies. Plos One.2013,8(2), e57121.
35 Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis.2013; 26(5):413-419.
36 Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology.2013; 2(3):e23562.
37 Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One.2013 7; 8(5):e63451.
38 Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K. Intra epithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immunity.2013;(13):1-7.
39 Bedewy M, El-Maghraby S, Bedewy A. CD 163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res.2013 Jun; 48(2):121-127.
40 Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, G6mez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcia de Herreros A, Casal I, Bonilla F, Pena C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci.2013; 104(4):437-444.
41 Cui YL, Li HK, Zhou HY,et al. Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac JCancer Prev.2013; 14(2):1003-1007.
42 Waidmann O, Koberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiβ M, Kronenberger B, Piiper A.. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol. 2013 Jun 17.
43.Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD 163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One.2013; 8(3):e59771.
44 Fjeldborg K, Christiansen T, Bennetzen M, J M Ller H, Pedersen SB, Richelsen BR.. The Macrophage-Specific Serum Marker, Soluble CD 163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss. Obesity (Silver Spring).2013 Mar 20.
45 Parkner T, S(?)rensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, M(?)ller HJ. Soluble CD 163:a biomarker linking macrophages and insulin resistance. Diabetologia.2012 Jun;55(6):1856-1862.
46 Sonier B, Strom A, Wang GS, Patrick C, Crookshank JA, Mojibian M, MacFarlane AJ, Scott FW. Antibodies from a patient with type 1 diabetes and celiac disease bind to macrophages that express the scavenger receptor CD 163. Can J Gastroenterol.2011 Jun; 25(6):327-329.
47 Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, Wheatcroft SB, Ponnambalam S. Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease. Int J Hypertens.2010; 2010:646929.
48 Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Moller HJ, Moestrup SK.1. Targeting the hemoglobin scavenger receptor CD 163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther.2012; 20(8):1550-1558.
49 Zhang N, Palmer AF. Liposomes surface conjugated with human hemoglobin target delivery to macrophages. Biotechnol Bioeng.2012; 109(3):823-829.